Chronic Pancreatitis - Pipeline Insight, 2025

This “Chronic Pancreatitis - Pipeline Insight, 2025,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chronic Pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Chronic Pancreatitis Understanding

Chronic Pancreatitis: Overview

Chronic pancreatitis is commonly defined as a continuing, chronic, inflammatory process of the pancreas, characterized by irreversible morphologic changes. Symptoms of chronic pancreatitis range widely and may include vomiting, constant dull, unremitting abdominal pain, epigastric tenderness, weight loss, steatorrhea and glucose intolerance. Chronic pancreatitis is usually a complication of recurrent episodes of acute pancreatitis. Diagnosis of chronic pancreatitis is based on medical history, physical examination, and through various tests like imaging tests, endoscopic retrograde cholangiopancreatography, magnetic resonance cholangiopancreatography, and endoscopic ultrasonography. Treatment for chronic pancreatitis includes medical, endoscopic and surgical therapy. Pancreatic enzyme supplementation may be helpful in reducing pain.

'Chronic Pancreatitis - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Pancreatitis pipeline landscape is provided which includes the disease overview and Chronic Pancreatitis treatment guidelines. The assessment part of the report embraces, in depth Chronic Pancreatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Pancreatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pancreatitis R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Pancreatitis.

Chronic Pancreatitis Emerging Drugs Chapters

This segment of the Chronic Pancreatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Pancreatitis Emerging Drugs

Oral CRAC channel inhibitors: CalciMedica

CalciMedica is developing oral CRAC channel inhibitors for chronic indications treated in an outpatient setting. The drug is in pre-clinical studies for the treatment of Chronic Pancreatitis.

NI-03: Kangen Pharmaceuticals

NI-03 (camostat mesilate) is an orally administered serine protease inhibitor that reduces pancreatic enzyme activity. The drug is in Phase I/II clinical studies for the treatment of Chronic Pancreatitis. The drug has been approved in Japan but has not been approved in the United States.

Chronic Pancreatitis: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Pancreatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Pancreatitis

There are approx. 6+ key companies which are developing the therapies for Chronic Pancreatitis. The companies which have their Chronic Pancreatitis drug candidates in the most advanced stage, i.e. Phase II include, AzurRx.

Phases

The report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Pancreatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Pancreatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Pancreatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Pancreatitis drugs.

Chronic Pancreatitis Report Insights

• Chronic Pancreatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Pancreatitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Pancreatitis drugs?
• How many Chronic Pancreatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Pancreatitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Pancreatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Pancreatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CalciMedica
• GNT Pharma
• Koligo Therapeutics
• Kangen Pharmaceuticals
• AzurRx SAS
• Theraly Fibrosis

Key Products

• Oral CRAC inhibitor
• Flusalazine
• KT CP 203
• NI-03
• MS1819-SD
• TLY012